Discovery of VU0467319: an M1 Positive Allosteric Modulator Candidate
Author Information
Author(s): Poslunsey Michael S., Wood Michael R., Han Changho, Stauffer Shaun R., Panarese Joseph D., Melancon Bruce J., Engers Julie L., Dickerson Jonathan W., Peng Weimin, Noetzel Meredith J., Cho Hyekyung P., Rodriguez Alice L., Hopkins Corey R., Morrison Ryan, Crouch Rachel D., Bridges Thomas M., Blobaum Anna L., Boutaud Olivier, Daniels J. Scott, Kates Michael J., Castelhano Arlindo, Rook Jerri M., Niswender Colleen M., Jones Carrie K., Conn P. Jeffrey, Lindsley Craig W.
Primary Institution: Vanderbilt University
Hypothesis
Can VU0467319 serve as a selective M1 Positive Allosteric Modulator with minimal cholinergic side effects?
Conclusion
VU319 demonstrated the feasibility of selectively targeting central M1 muscarinic receptors without causing cholinergic adverse effects.
Supporting Evidence
- VU319 showed robust efficacy in multiple preclinical models of cognition.
- VU319 advanced into IND-enabling studies without significant adverse effects.
- The Phase I clinical trial indicated no cholinergic side effects.
- VU319 demonstrated high CNS penetration and favorable pharmacokinetics.
- VU319 was well tolerated in human volunteers at doses showing cognitive improvement.
Takeaway
VU319 is a new drug that helps improve thinking and memory without causing bad side effects that other similar drugs do.
Methodology
VU319 was tested in preclinical models and a Phase I clinical trial to assess its safety and efficacy.
Potential Biases
Potential bias in reporting positive outcomes from early clinical trials.
Limitations
The study primarily focused on preclinical and early clinical data, which may not fully predict long-term effects in broader populations.
Participant Demographics
Human volunteers in the Phase I trial, with no specific demographics provided.
Statistical Information
P-Value
0.0053
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website